|
赵正孝教授治疗慢性肝病合并骨质疏松症用药经验
|
Abstract:
目的:总结赵正孝教授从肝肾脾角度论治慢性肝病合并骨质疏松症的学术经验。方法:通过跟师待诊,收集临床验案,分析赵正孝教授从益肝补肾健脾角度对慢性肝病合并骨质疏松症发生发展过程中应用中药辩证论治思路的认识,并附一验案予以佐证。结果:赵正孝教授认为,肝郁脾肾虚是慢性肝病合并骨质疏松症发生发展的重要病机。所举验案辨证为肝郁脾肾亏虚证,赵正孝教授治以补益肝肾健脾,疗效显著。结论:基于上述认识,赵正孝教授从肝肾脾三脏入手,运用二灵补髓丹治疗慢性肝病之合并骨质疏松症者,初步观察具有较好的解除患者不适症状,提高骨量的作用,方简效弘,可供临床参考。
Objective: To summarize Professor Zhao Zhengxiao’s academic experience in treating chronic liver disease with osteoporosis from the perspective of liver, kidney, and spleen. Method: Through wait-ing with the teacher for consultation, clinical cases were collected to analyze Professor Zhao Zhengxiao’s understanding of the application of traditional Chinese medicine dialectical treatment in the occurrence and development of chronic liver disease combined with osteoporosis from the perspective of nourishing the liver, tonifying the kidney, and strengthening the spleen, and a case study was attached as evidence. Professor Zhao Zhengxiao believes that liver depression, spleen and kidney deficiency are important pathological mechanisms for the occurrence and development of chronic liver disease combined with osteoporosis. The case diagnosis is liver depression, spleen and kidney deficiency syndrome. Professor Zhao Zhengxiao’s treatment is to tonify the liver, kidney, and spleen, and has a significant therapeutic effect. Conclusion: Based on the above understanding, Pro-fessor Zhao Zhengxiao started with the liver, kidney, and spleen organs, and used the Er Ling Bu Sui Dan to treat patients with chronic liver disease complicated with osteoporosis. Preliminary obser-vations showed that it has a good effect on relieving discomfort symptoms and improving bone mass in patients. The formula is simple and effective, and can be used as a clinical reference.
[1] | Curtis, E.M., Moon, R.J., Dennison, E.M., et al. (2015) Recent Advances in the Pathogenesis and Treatment of Osteo-porosis. Clinical Medicine (London), 15, s92-s96. https://doi.org/10.7861/clinmedicine.15-6-s92 |
[2] | 王宏杰, 林龙帅, 赵庆华. 肝源性骨质疏松的发病机制研究[J]. 中国骨质疏松杂志, 2021, 27(4): 595-598. |
[3] | Filip, R., Radzki, R.P. and Bienko, M. (2018) Novel Insights into the Relationship between Nonalcoholic Fatty Liver Disease and Osteoporosis. Clinical Interventions in Aging, 13, 1879-1891. https://doi.org/10.2147/CIA.S170533 |
[4] | Manto-vani, A., Dauriz, M., Gatti, D., et al. (2019) Systematic Review with Meta-Analysis: Non-Alcoholic Fatty Liver Disease Is Associated with a History of Osteoporotic Fractures But Not with Low Bone Mineral Density. Alimentary Pharma-cology & Therapeutics, 49, 375-388. https://doi.org/10.1111/apt.15087 |
[5] | Mantovani, A., Gatti, D., Zoppini, G., et al. (2019) Association between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. Hepatology, 70, 812-823. https://doi.org/10.1002/hep.30538 |
[6] | Burt, L.A., Billington, E.O., Rose, M.S., et al. (2019) Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. JAMA, 322, 736-745.
https://doi.org/10.1001/jama.2019.11889 |
[7] | Bolland, M.J., Grey, A. and Avenell, A. (2018) Effects of Vitamin D Supplementation on Musculoskeletal Health: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. The Lancet Diabetes & Endocrinology, 6, 847-858.
https://doi.org/10.1016/S2213-8587(18)30265-1 |
[8] | Cai, J., Zhang, Z., Liu, J., et al. (2020) Correlation between Serum 25-OH Vitamin D Expression and Non-Alcoholic Fatty Liver Disease. Experimental and Therapeutic Medicine, 19, 1681-1686. https://doi.org/10.3892/etm.2020.8411 |
[9] | 崔璀, 吕颖捷. 鳖甲及其配伍药对现代药理学研究与临床应用述评[J]. 中医药学报, 2018, 46(3): 114-116.
https://doi.org/10.19664/j.cnki.1002-2392.180098 |
[10] | 石萍, 鲁增辉, 游华建, 等. 龟甲胶的现代研究进展[J]. 中国民族民间医药, 2018, 27(2): 59-62. |
[11] | 任辉, 张志达, 梁德, 等. 龟板改善激素性骨质疏松大鼠骨量、骨微细结构、骨生物力学和骨代谢的机制探讨[J]. 中华中医药杂志, 2016, 31(5): 1858-1862. |
[12] | 邱芸. 白术对骨质疏松症大鼠部分血生化指标影响分析[J]. 中国民族民间医药, 2013, 22(22): 9. |
[13] | 高文鑫, 陈云刚, 姚康, 等. 骨碎补治疗骨质疏松症的实验研究进展[J]. 中国骨质疏松杂志, 2022, 28(11): 1683-1689. |